Accéder au contenu
Merck
Toutes les photos(1)

Documents

361275

Sigma-Aldrich

3′-Deoxy-3′-fluorothymidine

97%

Synonyme(s) :

3′-Fluoro-2′,3′-dideoxythymidine, 3′-Fluorodeoxythymidine

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C10H13FN2O4
Numéro CAS:
Poids moléculaire :
244.22
Numéro MDL:
Code UNSPSC :
41106305
ID de substance PubChem :
Nomenclature NACRES :
NA.22

Pureté

97%

Forme

solid

Pf

176-178 °C (lit.)

Température de stockage

2-8°C

Chaîne SMILES 

CC1=CN([C@H]2C[C@H](F)[C@@H](CO)O2)C(=O)NC1=O

InChI

1S/C10H13FN2O4/c1-5-3-13(10(16)12-9(5)15)8-2-6(11)7(4-14)17-8/h3,6-8,14H,2,4H2,1H3,(H,12,15,16)/t6-,7+,8+/m0/s1

Clé InChI

UXCAQJAQSWSNPQ-XLPZGREQSA-N

Informations sur le gène

human ... TK2(7084)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Application

Promising antiviral agent possessing activity similar to other 3′-deoxy-3′-substituted thymidines.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

P Herdewijn et al.
Journal of medicinal chemistry, 30(8), 1270-1278 (1987-08-01)
A series of 2',3'-unsaturated and 3'-substituted 2',3'-dideoxynucleoside analogues of purines and pyrimidines have been synthesized and evaluated for their inhibitory activity against human immunodeficiency virus (HIV). The 2',3'-unsaturated analogues of 2',3'-dideoxycytidine (ddeCyd) and 2',3'-dideoxythymidine (ddeThd), 3'-azido-2',3'-dideoxythymidine (AzddThd), 3'-fluoro-2',3'-dideoxythymidine, 2',3'-dideoxycytidine (ddCyd)
Julian L Goggi et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(9), 1630-1636 (2013-08-03)
Successful antiangiogenic therapies have been developed for the treatment of various cancers, but not all patients respond. Therefore, the early determination of therapy efficacy is essential for patient management. This study was done to evaluate the utility of various PET
Yuka Yamamoto et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 53(12), 1911-1915 (2012-10-20)
We evaluated 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) uptake in patients with newly diagnosed and recurrent gliomas and correlated the results with tumor grade and proliferative activity. (18)F-FLT PET was investigated retrospectively in 56 patients, including 36 with newly diagnosed gliomas and 20 with
Nicolas Graf et al.
European journal of nuclear medicine and molecular imaging, 40(1), 34-43 (2012-10-12)
Positron emission tomography (PET) with the thymidine analogue [(18)F]fluorothymidine ([(18)F]FLT) has been shown to detect early response to chemotherapy in high-grade lymphoma. In this preclinical in vitro and in vivo study we compared [(18)F]FLT to the glucose analogue [(18)F]fluorodeoxyglucose ([(18)F]FDG)
Eliot T McKinley et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(3), 424-430 (2013-01-24)
Selective inhibition of oncogenic targets and associated signaling pathways forms the basis of personalized cancer medicine. The clinical success of (V600E)BRAF inhibition in melanoma, coupled with the emergence of acquired resistance, underscores the importance of rigorously validating quantitative biomarkers of

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique